The science is ready.
The regulators agree.
The FDA Modernization Act 2.0 explicitly enables non-animal testing methods. Azunic's platforms already run the five-step pipeline that FDA reviewers expect to see.
12–16 weeks
Compressing what used to take years of animal studies into a fraction of the timeline.
Proven against legacy methods
DILI Retrospective Study
Across 847 compounds with known human hepatotoxicity outcomes. Reference dataset: DILIrank.
Renal Toxicity Panel
Against clinical nephrotoxicity signals from post-market surveillance data across 12 drug classes.
Cardiac Safety (hERG)
Head-to-head comparison with patch-clamp gold standard on 200 compounds. ICH S7B aligned.
Built to satisfy the people who sign off on your filing.
The FDA Modernization Act 2.0 (2022) removed the animal testing mandate from US drug applications. EMA and PMDA are aligned, and ICCVAM actively promotes NAMs. Every Azunic dossier is structured to match what these reviewers already expect to see.
Ready to leave animal testing behind?
Speak with our scientists. Get an assessment of your compound against our NAM platform.
